ALSG consensus for advanced stage MCL in young, fit patients Current practice for induction therapy in young, fit patients differs across Asia based on drug availability and reimbursement status. Few physicians use HyperCVAD; however, this approach risks omitting or reducing the dose of cytarabine, which plays an important role in induction therapy and may be the most useful drug. Cytarabine has an important role in induction therapy in MCL, but there is a lack of data supporting the best cytarabine dosage and dosing interval. The interaction between cytarabine and purine analogs should be considered to address concerns around cytarabine dose and toxicity. Clinical trial enrollment is strongly suggested where possible, especially for patients with TP53 mutation, which is associated with poor prognosis by conventional treatment.